378) Conventional treatment approaches, such as surgery, che |
379) and psychosexual adjustment after cancer treatment are needed. |
380) Ambient/room temperature settings in burn treatment areas vary greatly due to a lack |
381) Adherence was assessed by the treatment attendance rates, and maintenanc |
382) uentially allocating patients to the best treatment based on the responses of patien |
383) X5 to be an oncogenic target and a cancer treatment-resistant biomarker, a few studi |
384) eview identified preliminary evidence for treatment-dependent brain changes in adult |
385) way to assess the clinical efficacy of a treatment by combining the results of rand |
386) However, before incorporation into treatment can occur, there is a need for r |
387) been researched to support Canadian post-treatment cancer survivors; and (2) analyz |
388) derstanding of each stage of the 90:90:90 treatment cascade (as proposed by UNAIDS), |
389) s from tumor and tumor-adjacent tissue of treatment-naive ccRCC resections. |
390) , study characteristics and day programme treatment characteristics, then narrativel |
391) ds were evaluated for factors influencing treatment choices, with particular attenti |
392) 10 studies, 37 (34%) included a nutrition treatment component. |
393) any of the treatments consisted of common treatment components occurring in both net |
394) Treatment comprises conservative treatment |
395) A and/or DHA supplementation pre- or post-treatment, concomitant with neoadjuvant ch |
396) e is used to relate outcome to period and treatment condition. |
397) ors (e.g., adverse reactions, duration of treatment, cost of treatment), and patient |
398) With mental health-related treatment costs and economic burden only p |
399) sed to evaluate if and how corticosteroid treatment could influence disease outcome |
400) ta-analyses (NMAs) increasingly assist in treatment decisions in disease areas such |
401) The treatment decreased prolyl hydroxylation, |
402) Loss to follow-up and treatment delays could be addressed by imp |
403) Current treatment depends on empirical patient and |
404) However, the between-treatment differences are not always signi |
405) Due to the urgent need for effective treatment, drug repurposing is regarded as |
406) gal drugs are available for aspergillosis treatment, e.g., azoles, but the emergence |
407) delivered over short periods may improve treatment efficiency while maintaining eff |
408) for selecting a specific regimen and for treatment eligibility criteria were poorly |
409) zed stigma was related to lower levels of treatment engagement. |
410) Metabolic studies revealed that high salt treatment enhanced the glycolytic reserve |
|